G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Market Growth Outlook Reveals A CAGR Of 13% And A Market Value Of $4.88 Billion By 2030
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The market for structure-based drug design targeting G protein-coupled receptors (GPCR) has experienced rapid expansion in recent years. Projections indicate that it will rise from $2.64 billion in 2025 to $3 billion in 2026, representing a compound annual growth rate (CAGR) of 13.3%. Historical growth has been driven by advancements in GPCR crystallography methods, heightened investment in pharmaceutical research and development, access to high-resolution receptor structures, an improved comprehension of GPCR signaling pathways, and the broadening of small molecule drug discovery frameworks.
The market for structure-based drug design targeting G protein-coupled receptors (GPCRs) is anticipated to experience rapid expansion over the coming years. By 2030, its value is projected to reach $4.89 billion, reflecting a compound annual growth rate (CAGR) of 13.0%. This forecasted growth is driven by several factors, including the growing use of AI-assisted molecular design, a heightened emphasis on precision medicine in drug development, the broadening of GPCR targets within oncology and neurology, increased funding for next-generation structural biology tools, and a rising need for highly selective therapeutic agents. Key trends shaping this period involve the more frequent application of structure-guided ligand optimization, the growing utilization of cryo-electron microscopy for GPCR analysis, the deeper integration of computational modeling into drug discovery processes, the expansion of allosteric modulator development, and a stronger focus on improving receptor selectivity.
Download A Free Sample Report For Comprehensive Market Insights:
G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Market Demand Drivers Creating New Revenue Opportunities
The growth of the G protein-coupled receptors (GPCR) structure-based drug design market is anticipated to be fueled by a rising need for precision medicine. These treatment strategies utilize specific biological markers to tailor therapies according to individual patient characteristics and disease profiles. The increasing preference for precision medicine is attributed to its better effectiveness and fewer adverse effects relative to conventional treatments, as healthcare systems adopt a stronger focus on personalized approaches that address distinct molecular pathways instead of broad-spectrum interventions. This heightened emphasis on precision medicine directly boosts the adoption of GPCR structure-based drug design platforms, as pharmaceutical companies depend more on advanced computational tools to pinpoint and refine receptor-specific compounds that achieve the molecular accuracy required for personalized therapies. As an example, the Personalized Medicine Coalition, a US non-profit, reported that in February 2024, the FDA sanctioned 16 new personalized treatments for rare diseases in 2023, a notable jump from six approvals in 2022. Of these newly authorized drugs, seven are for cancer, while three target other illnesses and conditions. Consequently, the growing demand for precision medicine is propelling expansion in the GPCR structure-based drug design market.
G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Market Segment Performance And Strategic Opportunities
The g protein-coupled receptors (gpcr) structure-based drug design market covered in this report is segmented –
1) By Drug Type: Small Molecule Drugs, Biologics, Peptides, Other Drug Types
2) By Technology: X-Ray Crystallography, Cryo-Electron Microscopy, Computational Modeling, Nuclear Magnetic Resonance Spectroscopy, Other Technologies
3) By Application: Oncology, Cardiovascular Diseases, Neurological Disorders, Metabolic Disorders, Other Applications
4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Small Molecule Drugs: Agonists, Antagonists, Allosteric Modulators, Enzyme Inhibitors
2) By Biologics: Monoclonal Antibodies, Therapeutic Proteins, Vaccines, Fusion Proteins
3) By Peptides: Linear Peptides, Cyclic Peptides, Modified Peptides, Peptidomimetics
4) By Other Drug Types: Nucleic Acid Based Drugs, Cell Based Therapies, Gene Therapies, Conjugated Drugs
G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Market Trends Driving Strategic Industry Expansion
Major pharmaceutical firms in the G-protein coupled receptor (GPCR) structure-based drug design market are placing significant emphasis on developing advanced solutions like structure-based drug design platforms to expedite the creation of new drugs and enhance therapeutic precision. These platforms combine computational modeling and experimental methods, leveraging the three-dimensional (3D) configuration of target proteins to refine and select drug candidates, ultimately enabling the identification of more accurate, effective, and safer treatments. A notable example occurred in January 2025, when Septerna Inc., a US-based pharmaceutical enterprise, unveiled fresh efforts to expand its Native Complex Platform, supported by the $100 million Series A funding previously acquired. By preserving the natural structure and dynamic behavior of GPCRs outside the cell environment, this platform facilitates structure-based drug design tailored to these receptors. It aids in building a pipeline of GPCR-focused therapies aimed at previously inaccessible targets across diverse therapeutic fields, while also establishing a scalable framework for industrialized drug discovery, the incorporation of novel screening techniques, and the exploration of new GPCR modulation mechanisms. Furthermore, the platform creates avenues for systematically examining the complete GPCR superfamily, thereby broadening the scope of potential therapeutic applications.
G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the g protein-coupled receptors (gpcr) structure-based drug design market are F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi S.A., AstraZeneca plc, Thermo Fisher Scientific Inc., Boehringer Ingelheim International GmbH, WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., Evotec SE, Acadia Pharmaceuticals Inc., Promega Corporation, Domain Therapeutics SA, Schrödinger Inc., Kallyope Inc., Domainex Ltd., Structure Therapeutics Inc., Creative Biolabs Inc., InterAx Biotech Inc., Abalone Bio Inc., Octant Inc.
Access The Complete G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Market Report:
G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the G protein-coupled receptors (GPCR) structure-based drug design market in 2025. The regions covered in the g protein-coupled receptors (gpcr) structure-based drug design market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
